Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 4/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | HCK | P08631 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 4/20 | 0.37 |
| ▸ | F2 | P00734 | 3/20 | 0.37 |
| ▸ | PLAU | P00749 | 3/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2083930 | 0.85 | ESR1 (0.44) | HSD17B1ESR1ESR2ELANEF2 | |
| SCHEMBL27761403 | 0.81 | HSD17B1 (0.45) | HSD17B1ESR1ESR2PIK3CDABL1 | |
| SCHEMBL2082968 | 0.78 | MAPT (0.44) | HSD17B1ESR1ESR2KDM4EHSD17B10 | |
| SCHEMBL498148 | 0.78 | HSD17B1 (0.40) | HSD17B1ESR1ESR2MAPTALDH1A1 | |
| SCHEMBL498197 | 0.76 | ELANE (0.51) | ELANEF2PLAUKDM4EHSD17B10 | |
| SCHEMBL19127270 | 0.76 | ELANE (0.42) | ELANEF2PLAUKDM4EHSD17B10 | |
| SCHEMBL30711997 | 0.76 | ELANE (0.42) | ELANEF2PLAUKDM4EHSD17B10 | |
| SCHEMBL2085082 | 0.74 | MAPT (0.49) | HSD17B1ESR1ESR2KDM4EHSD17B10 | |
| SCHEMBL497991 | 0.74 | NR4A2 (0.51) | HSD17B1ESR1ESR2MAPT | |
| SCHEMBL2081737 | 0.74 | HSD17B1 (0.43) | HSD17B1ESR1ESR2ABL1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984360-B1 | Compounds and methods for modulating FX-receptors | LILLY CO ELI (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8106077-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| CN-101374834-B | Compounds and methods for modulating FXR | ELI LILLY AND CO. (US) | 2011-12-14 | — | — | CN | disclosed |
| US-7863302-B2 | Compounds and methods for modulating FX-receptors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| EP-2029558-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-04-09 | — | — | US | disclosed |
| EP-2029558-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| CN-101374834-A | Compounds and methods for modulating FXR | LILLY CO ELI (US) | 2009-02-25 | — | — | CN | disclosed |
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2008-12-11 | — | — | US | disclosed |
| WO-2007140174-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | F2R, TBXA2R, PTAFR | HSD17B1 840/4885ESR1 896/4885ESR2 342/4885 |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | HSD17B1 119/4885ESR1 2766/4885ESR2 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.